The CASP7 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CASP7 gene in the A2780 human ovarian carcinoma cell line. This loss-of-function model is generated by CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of knockout cells suitable for functional studies without clonal selection bias.
The A2780 host cell line is an epithelial ovarian adenocarcinoma model originally derived from an untreated patient. It is widely used in chemoresistance research, exhibiting well-characterized responses to platinum and taxane drugs, and retains relevant signaling pathways for ovarian cancer biology.
CASP7 encodes caspase-7, an executioner caspase that catalyzes the cleavage of cellular substrates to execute apoptosis. It is activated by initiator caspases (caspase-8, -9, -10) or granzyme B following stimulation of death receptors (Fas, TRAIL) or mitochondrial release of cytochrome c and Apaf-1. Activated caspase-7 proteolytically processes proteins such as PARP, lamin A/C, ICAD/DFF45, gelsolin, ROCK1, and PAK2, leading to DNA fragmentation, nuclear lamina disassembly, and cytoskeletal reorganization. Its enzymatic activity is inhibited by XIAP, survivin, and cIAP1/2, and modulated by interactions with Hsp70 and 14-3-3. Caspase-7 functions in both intrinsic and extrinsic apoptotic signaling and has been implicated in inflammatory responses, highlighting its role at the interface of cell death and immune regulation.
In the A2780 ovarian adenocarcinoma model, CASP7 knockout provides a critical tool to explore apoptosis resistance mechanisms. Ovarian carcinomas frequently evade chemotherapy-induced cell death, and loss of caspase-7 function may underlie acquired drug resistance. This polyclonal knockout population allows researchers to assess chemosensitivity to standard agents like cisplatin and paclitaxel, and to screen for synthetic lethal interactions or alternative death pathways. Additionally, it enables dissection of caspase-7-dependent inflammatory signaling that can shape the tumor microenvironment.
This knockout product supports diverse applications including apoptosis mechanistic studies, drug resistance profiling, functional genomics, and validation of cancer therapeutic targets. It is compatible with downstream assays such as western blotting, RT-qPCR, annexin V/propidium iodide flow cytometry, caspase activity assays, MTT/XTT cell viability tests, drug sensitivity dose-response experiments, and transcriptomic analysis via RNA-seq. The polyclonal format minimizes clonal artifacts and is well-suited for high-throughput phenotypic screens. For additional technical information, please contact Ascent Research.
